search results for: Retrophin

LB Phar­ma­ceu­ti­cals rais­ing $75M for schiz­o­phre­nia drug as Karuna looks to change the field

7 months ago
Financing
Startups

Tra­vere Ther­a­peu­tics just miss­es on con­fir­ma­to­ry study for kid­ney dis­ease drug, stock plum­mets

7 months ago
R&D

Chi­nook de­lays topline kid­ney con­di­tion da­ta; Elu­minex ropes in $40M+ in a Se­ries B

Last year
News Briefing

FDA clears Tra­vere’s rare kid­ney dis­ease drug, will come with REMS pro­gram

Last year
Pharma
FDA+

BIO in tu­mult as CEO abrupt­ly ex­its; Some good PhI­II news; Da­ta is­sues still plague No­var­tis' gene ther­a­py; Hot ...

Last year
Weekly

FDA punts Travere's rare kid­ney dis­ease NDA for three months, re­quest­ing REMS up­date

Last year
FDA+

For­mer Spark ex­ec to lead a gene ther­a­py up­start of his own; Big Phar­ma mar­ket­ing vet named CEO of Swiss biotech

Last year
Peer Review

Hel­lo, I must be go­ing: Jorge Gomez is Mod­er­na CFO for on­ly a day; As set­backs mount, In­ovio’s Joseph Kim choos­es ...

Last year
Peer Review

‘Nat­ur­al evo­lu­tion’: Caris­ma’s sci­en­tif­ic co-founder moves in­to the CSO post; Vas Narasimhan en­lists Ron­ny Gal ...

Last year
Peer Review

'F--- the fed­s': Mar­tin Shkre­li barred from run­ning all pub­lic com­pa­nies as judge de­cries re­morse­less be­hav­ior

3 years ago
Pharma

How fam­i­ly and sci­ence moved Ex­elix­is' new CMO to work on on­col­o­gy block­busters; While John Maraganore racks up the ...

3 years ago
Peer Review

Cal­lid­i­tas nabs ac­cel­er­at­ed OK for rare kid­ney dis­ease, beat­ing two com­peti­tors to the punch

3 years ago
FDA+

Lu­ba Green­wood takes the helm at Ko­jin Ther­a­peu­tics, steer­ing an all-fe­male C-suite; Alex­ion R&D chief packs up for ...

3 years ago
Peer Review

Not so fast: FDA tacks 3 more months on­to de­ci­sion date for Cal­lid­i­tas' rare kid­ney dis­or­der drug

3 years ago
FDA+

Vac­citech makes short move to new head­quar­ters; En­ter­o­Bi­otix rais­es more than $21M in Se­ries A

3 years ago
News Briefing

Vac­cine man­dates, bio­phar­ma edi­tion; Alzheimer’s rip­ple ef­fect; Change of guard at J&J; and more

3 years ago
Weekly

Sev­er­al months af­ter re­brand­ing, an old Mar­tin Shkre­li com­pa­ny touts promis­ing piv­otal da­ta in a rare kid­ney dis­or­der

3 years ago
R&D

Pri­or­i­ty re­view vouch­er up­dates: Who's won PRVs, who's bought them, and how much they're sell­ing for

3 years ago
R&D
FDA+
1234 Next page Last page

latest

Most read

GSK ac­cus­es Pfiz­er and BioN­Tech of mR­NA patent in­fringe­ment

4 hours ago
Pharma
Law

Gilead leans on CymaBay liv­er drug, Trodelvy read­outs and long-ac­tive PrEP yet to come this year

28 minutes ago
R&D
Pharma

In rare move, Colom­bia is­sues com­pul­so­ry li­cense for HIV med­i­cine in ef­fort to ex­pand ac­cess

3 hours ago
Pharma
FDA+

Es­teve to ac­quire Per­rigo's rare dis­ease phar­ma busi­ness for up to $295M

4 hours ago
Deals
Pharma

FDA re­vis­es guid­ance on biosim­i­lar pro­mo­tion­al la­bels and ad­ver­tis­ing

4 hours ago
FDA+
Marketing
see latest stream
A service from the Financial Times